By selectively binding to PD-1 on TILs, AWT020 delivers a dual benefit: it blocks the inhibitory PD-1 pathway and provides IL-2 signaling to promote the expansion of tumor-antigen-specific T cells. The gene discussed is PDCD1; the disease is neoplasm.